Gene therapy shows promise for reversing age-related vision loss
Yuancheng (Ryan) Lu, a geneticist at the Whitehead Institute, developed a gene therapy that uses reprogramming to rejuvenate cells, successfully restoring vision in mice with crushed optic nerves. The therapy entered human clinical trials in June 2026, with a glaucoma patient receiving the injection. This approach could lead to new treatments for age-related blindness.
Lu's personal stakes are high, given his family's history of age-related blindness and his own genetic risk. In earlier research, he used a three-gene reprogramming method to regenerate damaged optic nerves in mice, restoring their sight within weeks.
That treatment, now called ER-100, was injected into a human glaucoma patient in June 2026 through Life Biosciences. The success has sparked significant venture capital interest, with tech billionaires funding similar anti-aging ventures like Altos Labs and NewLimit.
This therapy could transform treatment for age-related blindness, offering hope to millions with glaucoma or macular degeneration. If successful, it may shift the focus of medicine from managing chronic degeneration to actively reversing cellular aging. However, the approach carries potential risks, such as cancer from reprogramming genes, and long-term safety remains unknown. The high costs of such treatments could also limit access, potentially widening health disparities among older populations.